Wedbush Lowers Earnings Estimates for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at Wedbush decreased their Q1 2025 EPS estimates for Travere Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico now expects that the company will earn ($0.43) per share for the quarter, down from their previous estimate of ($0.42). The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.56) EPS.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The firm had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%.

Other research analysts have also issued research reports about the stock. Citigroup raised their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity Group raised their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Wednesday. Evercore ISI lifted their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Finally, Piper Sandler increased their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Stock Down 1.9 %

Shares of NASDAQ:TVTX opened at $20.64 on Thursday. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $25.29. The company has a market capitalization of $1.61 billion, a PE ratio of -5.03 and a beta of 0.72. The company has a fifty day moving average of $19.97 and a 200-day moving average of $16.91.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. grew its holdings in shares of Travere Therapeutics by 9.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company’s stock valued at $138,000 after purchasing an additional 667 shares during the last quarter. Creative Planning boosted its position in Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after buying an additional 995 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Travere Therapeutics during the fourth quarter valued at about $31,000. Sterling Capital Management LLC increased its holdings in shares of Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock worth $41,000 after buying an additional 2,115 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Travere Therapeutics by 2.2% in the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock valued at $2,112,000 after acquiring an additional 2,640 shares during the last quarter.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 54,244 shares of Travere Therapeutics stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the sale, the chief accounting officer now owns 54,410 shares of the company’s stock, valued at $1,360,250. The trade was a 49.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the transaction, the senior vice president now owns 83,170 shares in the company, valued at $1,618,488.20. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,335 shares of company stock valued at $4,453,012. Insiders own 4.06% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.